HCP2303

HCP2303 is an investigational drug developed by Hanmi Company Limited. Its mechanism of action is currently unknown, and it does not represent a novel mechanism. The drug is administered orally and has not received any regulatory approval or FDA designation. As of 2024, HCP2303 has completed phase 1 clinical trials in healthy volunteers and for malnutrition in Korea. No adverse events have been reported to date, and there are no approved indications or known brand names associated with this compound. HCP2303 may be a fixed-dose combination product, but the specific active ingredients and mechanisms remain undisclosed as of current public information. No additional diseases beyond malnutrition have been identified for development.